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Abstract
Protein–protein interactions (PPIs) determine a wide range of biological processes and analysis of
these dynamic networks is increasingly becoming a mandatory tool for studying protein function.
Using the globular ATPase domain of recombinase RadA as a scaffold, we have developed a pep-
tide display system (RAD display), which allows for the presentation of target peptides, protein
domains or full-length proteins and their rapid recombinant production in bacteria. The design of
the RAD display system includes differently tagged versions of the scaffold, which allows for ﬂexi-
bility in the protein puriﬁcation method, and chemical coupling for small molecule labeling or sur-
face immobilization. When combined with the signiﬁcant thermal stability of the RadA protein,
these features create a versatile multipurpose scaffold system. Using various orthogonal biophys-
ical techniques, we show that peptides displayed on the scaffold bind to their natural targets in a
fashion similar to linear parent peptides. We use the examples of CK2β/CK2α kinase and TPX2/
Aurora A kinase protein complexes to demonstrate that the peptide displayed by the RAD scaffold
can be used in PPI studies with the same binding efﬁcacy but at lower costs compared with their
linear synthetic counterparts.
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Introduction
Biochemical and biophysical characterization of protein–protein
interactions (PPIs) that regulate biological functions in all organisms
requires the use of recombinant proteins, many of which are difﬁcult
to produce in quantities required for these studies. Although in
many cases one of the binding partners can be replaced by linear or
cyclic peptides derived from the interfaces of PPIs (Benyamini and
Friedler, 2010; Katz et al., 2011), using peptides is limited by the
cost, time and feasibility of synthesis. This can signiﬁcantly restrict
the ability to probe the contribution of both the length and compos-
ition of the peptide to the binding interaction, and is particularly
pertinent for peptide sequences that are difﬁcult or impossible to
produce by solid phase synthesis. Furthermore, linear peptides are
prone to proteolysis and challenging to introduce into cells, compli-
cating their use in in vivo biological assays. Finally, in general, ﬂex-
ible molecules may have a lower afﬁnity to their targets than their
conformationally restrained variants (Ghosh et al., 2005; Laudet
et al., 2007; DeLorbe et al., 2009).
To overcome the limitations imposed by the properties of iso-
lated peptides, a variety of different peptide display technologies
have been developed (Table S1). Most of these rely on a small,
highly soluble and thermostable protein core or ‘scaffold’ that can
tolerate insertions into loop sequences or N-terminal extensions
(Binz et al., 2005; Reverdatto et al., 2015; Škrlec et al., 2015).
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Examples of such scaffolds include thioredoxin, Adhiron and
Afﬁmer (based on cystatins), kunitz domains, γ-S crystallin,
Adnectin and Pronectin (ﬁbronectin domains), Anticalin (from
lipocalins), Fynomer (tyrosine kinase) and Knottins (Binz et al.,
2005; Hoffmann et al., 2010; Lipovšek, 2011; Moody et al., 2012;
Schlatter et al., 2012; Cappuccilli et al., 2009; Tiede et al., 2014;
Škrlec et al., 2015).
Several surface display scaffolds were designed to model broad
surface-based PPIs and can tolerate mutations across an entire face
of the protein (Binz et al., 2005; Škrlec et al., 2015). Some peptide
display systems could potentially be used for development of med-
ical applications including diagnostic assays, imaging and protein-
based therapies (Binz et al., 2005; Mintz and Crea, 2013;
Haberkorn et al., 2014; Reverdatto et al., 2015; Škrlec et al., 2015).
However, the majority of these display systems were designed to
be used for in vitro directed evolution applications in iterative selec-
tion cycles to create novel binders with high afﬁnity for the target
protein and are often not well suited for biophysical interrogation of
PPIs by different, complementary methods. Thus, these scaffolds
were not suitable for our primary need in projects aimed at develo-
ping inhibitors against PPI involving linear epitopes.
To address this, we have developed a novel peptide display sys-
tem in which the epitope of choice is grafted onto a scaffold based
on the monomeric form of the RadA recombinase from Pyrococcus
furiosus. The advantage of using this particular scaffold is the fact
that RadA is a highly soluble medium-sized monomeric protein,
which possesses high thermal stability despite not containing any
cysteine residues. It has well-characterized structural organization
(Fig. 1a) and is tolerant of surface mutations and deletions (Scott
et al., 2013). This RadA scaffold allows also for rapid production in
Escherichia coli with high yields. In addition, a range of engineered
expression constructs with differently tagged versions of this RadA-
based scaffold (RAD) were created in order to facilitate immobiliza-
tion of displayed peptides on solid surfaces or labeling with ﬂuorescent
dyes (Fig. S1).
To evaluate the functionality of the RAD display system, we
have chosen to test two well-established protein interactions: TPX2/
Aurora A kinase and CK2β/CK2α kinase-subunit complex (Fig. S2).
Both complexes are therapeutically relevant and engage serine/threo-
nine kinases that play important roles in carcinogenesis. As such,
they serve as interesting model systems to demonstrate the usefulness
of the RAD display as a tool for analyzing PPIs.
Aurora A kinase plays an important role in the mitotic spindle
assembly and is overexpressed in tumor cells (Bischoff et al., 1998).
It is known to be dramatically activated by TPX2 protein, which
binds to the Aurora A catalytic domain and translocates the kinase
to the mitotic spindle during mitosis (Bischoff et al., 1998; Kufer
et al., 2002; Eyers et al., 2003). TPX2 has been shown to bind to
Aurora A through its N-terminal segment with 2.3 nM afﬁnity
(Anderson et al., 2007) and inhibitors of the TPX2/Aurora A inter-
action have been suggested to serve as potential therapeutic agents
for cancer treatments (Asteriti et al., 2010; Janecek et al., 2016). A
crystal structure of the TPX2/Aurora A peptide complex is available
and shows that a conserved 43 residue long segment from the very
N-terminus of TPX2 binds to the Aurora A catalytic domain through
two separate antiparallel peptide stretches connected by a non-
conserved ﬂexible linker (Bayliss et al., 2003) (Fig. S2a).
CK2α is a constitutively active kinase involved in cell growth, pro-
liferation and suppression of apoptosis, and is often overexpressed
in cancer cells (Landesman-Bollag et al., 2001; Zhang et al., 2015).
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Fig. 1 Overview of the RAD display system. (a) Sequence of the RAD expression plasmid LIC cloning site and schematic representation of peptides and a protein
domain grafted on the RAD display system. The structure on the left shows full-length RadA protein. The N-terminal domain that is removed at the position indi-
cated by a dashed line is shown in light gray and the C-terminal ATPase domain is shown in darker gray. The two spheres indicate the start and the end of the
L2 loop where the displayed epitopes are inserted. The small structural diagrams illustrate how the system can tolerate insertions of different sizes, provided
their N- and C-termini are in close proximity. (b) SDS-PAGE analysis of soluble fractions of the E. coli cell lysates after induction with IPTG before and after a 10 min
65°C heating step to precipitate most of bacterial proteins; the major remaining contaminant has not been identiﬁed, as it is easily removed in subsequent puriﬁca-
tion steps. The position of the RAD display protein is indicated by a square bracket. (c) Sequences of the CK2β and TPX2 peptides used in the binding assays, with
RAD scaffold-derived sequences highlighted in bold.
2 M.Rossmann et al.
The range of target substrates for CK2α is modulated by a scaffold
protein, CK2β, that forms a reversible protein complex with an
equilibrium binding constant (KD) of 5.4 nM (Martel et al., 2002).
A cyclic Pc peptide GCRLYGFKIHGCG derived from the C-terminal
segment of the CK2β subunit has been shown to bind to CK2α with
nanomolar afﬁnity (KD = 559 nM) and to act as an allosteric acti-
vator of CK2α (Raaf et al., 2013) (Fig. S2b). The crystal structure
of the complex between CK2α kinase and the Pc peptide revealed
that the peptide interacted with the N-lobe of the kinase in a man-
ner analogous to the interaction with the full-length CK2β subunit
(Lolli et al., 2012). Notably, the linear form of the Pc peptide was
found to be a less potent competitive inhibitor than the constrained
Pc peptide and inhibited the formation of CK2β/CK2α complex with
the IC50 of 30 μM, which was 10 times less potent than the cyclic Pc
peptide constrained by a disulﬁde bond (IC50 3 μM) (Laudet et al.,
2007).
Using three orthogonal biophysical techniques, we demonstrate
that both long and short peptides grafted on the RAD scaffold are
easily produced in bacteria and bind to their natural targets with
afﬁnities comparable to or better than the equivalent linear peptides.
To further prove the usefulness of the scaffold system in analyses
of PPIs, we have used the RAD system for alanine scanning of the
TPX2/Aurora A interaction and have identiﬁed hotspots on the
TPX2 that contribute to the high-afﬁnity Aurora A kinase binding
activity, demonstrating that this display system can be used as a low
cost surrogate for synthetic peptides and full-length proteins in both
biophysical and biochemical studies of PPIs.
Results
RAD scaffold design
To develop a novel peptide display system, we have taken advantage
of our observation that the thermostable recombinase RadA from
P. furiosus can tolerate sequence diversity on its so-called DNA
binding L2 loop (Fig. 1a) (Marsh et al., 2016). The monomeric ver-
sion of RadA recombinase missing 107 N-terminal residues retains
the solubility and thermostable properties of the full-length protein
(Scott et al., 2013). Due to its high isoelectric point, the untagged
globular ATPase domain of RadA is easily puriﬁed from E. coli
using cation exchange chromatography followed by size exclusion
chromatography (SEC), while afﬁnity-tagged versions are well suited
for rapid processing of multiple constructs in parallel, for example
for screening purposes. Additionally, the high thermal stability of
RadA allows for fast initial enrichment of the protein by a simple
heat treatment, where the bacterial lysate is heated at neutral pH to
65°C for 10 min and the precipitated E. coli proteins are removed
by centrifugation, resulting in a high level of purity prior to chroma-
tography (Fig. 1b). This feature can be particularly useful for rapid
screening of RAD display variants for binding activity.
Our previous work on RadA has shown that its so-called L2
loop of can be deleted without affecting the protein stability (Scott
et al., 2013). This loop is involved in binding to single- and double-
stranded DNA (Chen et al., 2008) and disordered in most structures
of RadA and its orthologs. Guided by analysis of various RadA
crystal structures (Pellegrini et al., 2002; Shin et al., 2003; Wu et al.,
2005), we chose residues A287 and G302 as the anchor points for
peptide insertion. As shown in the crystal structure of RadA
(Fig. 1a), these residues are close to each other in three-dimensional
space but also somewhat removed from the globular core such that
additional residues are unlikely to interfere with folding and stability
of RadA. In order to further minimize the effect of the scaffold on
the peptide properties, we generated short ﬂexible linkers on both
sides of the peptide insertion site and designed the DNA expression
construct to be compatible with ligation-independent cloning (LIC)
(Aslanidis and de Jong, 1990). This allows for insertion of any epi-
tope sequence using synthetic DNA oligonucleotides that are
annealed to form dsDNA with compatible 5′ssDNA overhangs into
the LIC-ready vector (Figs. S1 and S3).
Expression of all constructs in bacteria is regulated by the T7lac
promoter and designed to facilitate ﬂexibility in puriﬁcation and bio-
physical applications by including options for addition of an N-
terminal His6-tag and a unique cysteine that allows for site-speciﬁc
labeling and directional immobilization through the very N-terminus
of the display protein. Plasmids were constructed to express untagged,
His6-tagged, His6-Cys-tagged, Cys-tagged and Cys-Strep-tagged ver-
sions (Fig. S1). Further, a ﬁnal expression plasmid was created for
production of proteins with a high-afﬁnity N-terminal double-His6-
tag, with the two His-tags separated by an AviTag for site-speciﬁc
biotinylation by BirA biotin transferase (Schatz, 1993).
Production of RAD display proteins in E. coli
For the validation of the RAD peptide display system, we created
various RAD display constructs for the production of scaffolds car-
rying Aurora A and CK2a binding epitopes from TPX2 and CK2β,
respectively. DNA sequences encoding for residues 7–43 of human
TPX2 (TPX2) (Fig. 1c) and for residues 186–200 of human CK2β
(CK2β) were produced as synthetic oligonucleotides (Fig. 1c).
Double-stranded DNA fragments were then assembled by thermal
denaturation and annealing from contiguous overlapping comple-
mentary primers (Table S2) and then inserted into different pRAD
vectors (Figs. S1 and S3) using LIC (Aslanidis and de Jong, 1990;
Aslanidis et al., 1994). In the next step, the chimeric proteins were
tested for soluble expression in E. coli to thereby determine the tol-
erance of the RAD scaffold for both long and short peptide sequence
insertions. Scaffolds displaying TPX2 and CK2β peptides and their
variants could be produced in E. coli and rapidly puriﬁed using a
heat treatment step (Fig. 1b) followed by cation exchange and SEC.
On average ~10mg of pure protein could be produced from 1 l bac-
terial culture. All RAD display proteins used in this work are listed
in the Supplementary Material (Table S3).
For the interaction analyses, full-length CK2α kinase (CK2α) and
the kinase domains of Aurora A (Aurora AWT and Aurora AD274N)
were produced in E. coli and puriﬁed to homogeneity.
Analysis of complex formation using sedimentation
velocity analytical ultracentrifugation and analytical
SEC
To demonstrate the possibility of studying complex formation between
the kinases and peptides displayed on the RAD scaffold, protein mix-
tures were subjected to sedimentation velocity analytical ultracentrifu-
gation (SV AUC) with UV absorbance detection at 280 nm.
SV AUC is a widely used technique to study proteins and protein
interactions and provides information on the size and shape of mole-
cules in solution (Schuck et al., 2001; Schuck, 2013). Figure 2 shows
results from the hydrodynamic measurements for the kinases and
RAD display proteins and their corresponding complexes. Fitting
the sedimentation velocity proﬁles with a single species Lamm
equation model revealed that both CK2α kinase and RAD-CK2β sedi-
ment as single species with s-values of 3.0 S and 2.3 S, respectively
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(Fig. 2a, Fig. S4a and b). The analysis of the boundary spreading of
the data shown in Fig. 2a shows molar masses of 41.5 kDa for CK2α
kinase and 28.0 kDa for RAD-CK2β, which is virtually identical to
the molar mass of the monomeric CK2α of 39.9 kDa and RAD-CK2β
of 28.1 kDa calculated from the amino acid composition of the
expression constructs. In contrast, for the CK2α/RAD-CK2β mixture,
we observed a single species that sedimented with an s-value of 3.8 S
(Fig. 2a, Fig. S4c). Sedimentation data analysis resulted in an esti-
mated molar mass of 59.3 kDa for the 3.8 S species, which strongly
indicated that the proteins formed a 1:1 complex in solution (calcu-
lated molar mass of the CK2α/RAD-CK2β complex is 68 kDa).
Similarly, SV AUC experiments conﬁrmed formation of a hetero-
dimeric protein complex between Aurora AD274N and RAD-TPX2
in solution deﬁned by the appearance of a larger species with a sedi-
mentation coefﬁcient of 3.6 S (Fig. 2b, Fig. S4d–f) compared with
the species proﬁles obtained in the experiments with individual pro-
teins alone. The analysis of the boundary spreading in the sedimenta-
tion velocity experiments with the Aurora AD274N and RAD-TPX2
mixture resulted in a molar mass estimate of 54.7 kDa, suggesting
that the observed 3.6 S species is a hetero-dimeric complex. A small
(<10%) population of species was also observed to sediment at 2.5 S
(Fig. 2b, Fig. S4f), which could be attributed to the unbound mono-
meric kinase or display proteins.
In contrast, Aurora AD274N kinase domain and RAD-TPX2 sedi-
ment with s-values of 2.6 S and 2.5 S, respectively (Fig. 2b, Fig. S4d
and e). This resulted in an estimated molar mass of 34.5 kDa for
Aurora AD274N kinase and 31.9 kDa for RAD-TPX2 display, which
was in line with theoretical molar masses of 33.8 and 30.4 kDa for
the kinase domain and RAD display, respectively.
In order to demonstrate that the stoichiometry of interactions
between the RAD display protein and their cognate binding partners
can be analyzed using more commonly available techniques, we also
subjected CK2α kinase, RAD-CK2β and an equimolar mixture to
analytical size exclusion over a Superdex 75 5/150 column (Fig. 2c
and d), Both CK2α kinase and RAD-CK2β elute as single species at
1.48 and 1.72ml, respectively. Calibration controls (Fig. S5) deter-
mine that these elution volumes are equivalent to molecular weights
of 45.7 and 22 kDa for CK2α kinase and RAD-CK2β, respectively,
consistent with the calculated and AUC determined molecular
weights (above). The mixture of the two proteins eluted as a single
species with a peak at 1.32ml, equivalent to a molecular weight of
74.3 kDa indicating that CK2α kinase and RAD-CK2β form a 1:1
complex consistent with the AUC data above (Fig. 2, Fig. S4).
Comparison of linear or displayed peptides for binding
to their targets
We next compared the afﬁnities of TPX2 and CK2β to their corre-
sponding kinase partners both as displayed on the RAD scaffold
and as isolated peptides. Sequences of the peptides were identical
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between the display versions and the linear peptides, but suitable
chemical handles were introduced to the ends of the peptides to
enable site-speciﬁc labeling or immobilization. Whereas short linear
CK2β peptide variants were synthesized chemically (Fig. 1c,
Fig. S6a), the signiﬁcantly longer TPX2 peptide has proven difﬁcult
to synthesize using standard solid phase chemistry and was pro-
duced in E. coli using the KSI fusion system (Kuliopulos and Walsh,
1994) (Fig. 1c, Fig. S6b).
To demonstrate that the RAD system is suitable for application
to the commonly used afﬁnity determination techniques, isolated
peptides and RAD proteins carrying the same peptide sequences
were used to determine and compare their afﬁnities to CK2α and
Aurora AD274N kinase using three complementary methods for
determination of the equilibrium binding constant (KD): isothermal
titration calorimetry (ITC), surface plasmon resonance (SPR) and
ﬂuorescence anisotropy (FA). The three analytical methods are
standard techniques and have their different strengths, weaknesses
and analyte requirements and provide complementary data on the
interactions.
ITC measures the heat that is released or absorbed during a
binding event, and allows for the determination of the thermo-
dynamic parameters for the interaction. ITC requires signiﬁcant
quantities of both interacting components, with the component to
be titrated into the sample cell needing to be stable and soluble at
reasonably high concentrations.
By contrast, SPR analysis demands less of the sample, but
requires one of the binding partners to be immobilized on the dex-
tran matrix on the sensor surface, ideally in a deﬁned orientation.
Additionally, the immobilized component needs to be sufﬁciently
stable to withstand repeated regeneration cycles without losing its
activity.
FA assays can be performed in solution at very low concentra-
tions of analytes and in very small volumes and with high-
throughput, compared with the ITC and SPR that are low- and
medium-throughput methods, respectively. The disadvantage of the
FA method is that it requires one binding partner to be ﬂuorescently
labeled, preferably in a homogenous fashion.
ITC analyses
To evaluate the use of RAD system for afﬁnity determination, stand-
ard ITC experiments were conducted at 25°C. To determine the
basic thermodynamic binding parameters, puriﬁed CK2β and TPX2
peptides and their RAD display variants were titrated to CK2α or
Aurora AD274N kinase domain (Fig. S7), respectively.
In the ITC assay, both display peptides performed with the same
efﬁcacy in the binding assays as their corresponding linear versions
(Table I). For the CK2β/CK2α interaction, the binding afﬁnity was
138 and 140 nM for the peptide and RAD-CK2β display, respect-
ively (Fig. 3a and d, Fig. S7 and Table I). The binding constant KD
for the Aurora AD274N interaction with RAD-TPX2 display or
TPX2 peptide was found to be 147 and 115 nM, respectively
(Fig. 4a and d, Fig. S7 and Table I). Thus, these ITC experiments
demonstrated the ability of the scaffold to present peptide epitopes
of different lengths without loss of the binding afﬁnity to the target
protein compared with the linear peptides.
ITC measurements suggested that the RAD scaffold did not pro-
mote signiﬁcant peptide pre-organization as the binding energetics
show no entropic advantage for either of the test complexes. For
both complexes, we observed very similar afﬁnities between the lin-
ear parent peptide and the peptide grafted on the RAD scaffold
(Table I). For both kinases, unfavorable entropic contributions were
observed for the interaction with the displayed peptides consistent
with the observations made by others (DeLorbe et al., 2009;
Udugamasooriya and Spaller, 2008). While in the case of Aurora
A/TPX2 interaction we observed only minor differences in relative
enthalpies and entropies (Fig. S8a–d), for CK2α, the interaction
with the RAD display showed a larger entropic penalty than when
binding to the peptide.
SPR analyses
SPR requires one of the two interacting partners to be immobilized
to the sensor surface without signiﬁcant loss while the other partner
(analyte) is ﬂowed over the surface. The interaction is detected by
the change in the refractive index of the surface as the analyte binds
to the immobilized partner. For the interaction to occur, the immo-
bilized partner needs to be positioned in a suitable orientation and
away from the dextran matrix on the surface so as not to be steric-
ally hindered. With linear peptides this can be difﬁcult to achieve
without introducing additional linkers to the end of the peptide that
is being immobilized. A larger scaffold displaying the peptide would
ensure the binding epitope is accessible on the surface.
With the RAD display system, we have overcome these possible
limitations by introducing a unique cysteine residue in the very N-
terminus of the protein to enable site-speciﬁc immobilization using
maleimide chemistry. As the N-terminus of the domain is on the
opposite side from the inserted peptide epitope, the displayed pep-
tide will be positioned well away from the SPR surface and exposed
to the analyte. Also, the immobilized partner needs to be stable
enough to allow for the bound analyte to be dissociated, typically
under relatively harsh conditions and the surface regenerated in
order to bind to the analyte again.
We tested the promise of RAD to facilitate SPR measurements
using both of our test systems. The CK2β peptide presented by the
cRAD system had a 3-fold higher afﬁnity (KD = 237 nM) for the
CK2α kinase compared with the linear peptide immobilized on the
CM5 chip surface (KD = 407 nM) (Table I, Fig. 3b and e, Fig. S9a
and b). The synthetic peptide had the same sequence as the RAD-
displayed epitope, with two additional residues in its C-terminus
(Gly-Cys) to enable covalent coupling to the surface. It seems that
grafting of the short CK2β peptide onto the RAD scaffold brought
advantage for the SPR assay and resulted in a more comparable KD
value to what was determined by ITC.
In the SPR assays, Aurora A/TPX2 interactions demonstrated
slow dissociation, but analysis of the kinetic data was not possible
using the expected 1:1 binding model and could only be modeled
Table I. Summary of the afﬁnity data
Complex Method Peptide (nM) RAD peptide (nM)
TPX2(7–43) /Aurora AD274N ITC 115 ± 10 147 ± 10
SPR 72 ± 14 168 ± 14
FA 74 ± 5 98 ± 19
CK2β(186–200) /CK2α ITC 138 ± 13 140 ± 19
SPR 407 ± 50 237 ± 17
FA 348 ± 27 139 ± 48
Equilibrium dissociation constants (KD) for CK2β(186–200)/CK2α kinase and
TPX2(7–43) /Aurora AD274N kinase determined for linear peptides and peptides
presented by the RAD display using different methods. The data were typic-
ally derived from a single titration experiment and the conﬁdence interval
(±KD) was estimated from the ﬁtting.
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using a heterogenous ligand model. It is unclear where this hetero-
geneity originates from, both the free and RAD-displayed TPX2
demonstrate similar behavior (Fig. S9e and f and associated ﬁgure
legend), it seems to reﬂect the properties of the peptide, possibly dif-
ferent solution conformations or alternative binding modes.
Analyzing the data using a steady-state model, TPX2 peptide dis-
played on the RAD scaffold bound Aurora AD274N with an afﬁnity
comparable to the linear TPX2 peptide. The 45 amino acid long lin-
ear TPX2 peptide bound to Aurora AD274N with KD values within
an ~2-fold range of the values observed for RAD-displayed peptide
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(Table I, Fig. 4b and e, Fig. S9c and d). These values were also com-
parable to the ones obtained by ITC (Table I).
FA measurements
The FA method allows rapid and quantitative analysis of molecular
interactions in solution. This technique requires one of the binding
partners to be labeled with a ﬂuorescent tracer. The label is prefer-
ably attached to the smaller binding partner in order to maximize
the dynamic range of the assay. Both RAD-TPX2 and RAD-CK2β
display proteins were labeled with Alexa Fluor 488-maleimide using
the unique N-terminal cysteine introduced by the cRAD scaffold.
For the CK2β/CK2α interaction, the binding afﬁnity was determined
to be 348 nM for the peptide and 139 nM for the RAD-CK2β dis-
play (Table I, Fig. 3c and f). The ~3 times weaker afﬁnity of the
ﬂuorescein labeled linear CK2β peptide compared with the display
may reﬂect the negative effect of the ﬂuorescent tracer being located
proximally to the short peptide during the formation of the complex
and is in line with the similar effect seen in SPR. This could possible
be overcome by using a longer peptide, but we deliberately used the
core peptide epitope for the FA experiment as this would be
expected to yield largest difference in FA upon binding. It is worth
noting that afﬁnities measured for RAD-displayed CK2β peptide are
more consistent (139–237 nM) between the different experimental
techniques than those measured for the peptide (138–407 nM).
The binding afﬁnity for the TPX2/Aurora AD274N complex was
found to be similar for the linear TPX2 peptide and RAD-TPX2 (KD
= 74 nM for the linear peptide and KD = 98 nM for the RAD dis-
play). Even with the comparatively narrow dynamic range of the FA
assay while using ﬂuorescently labeled RAD display as tracers, the
obtained KD values were comparable to those using labeled linear
peptide, which had a much broader dynamic range (Table I, Fig. 4c
and f).
Hotspots in TPX2: Aurora A binding site
To resolve the residues or ‘hot spots’ in the TPX2 peptide that drive
afﬁnity for Aurora A, a double His-tagged RAD scaffold was utilized
to produce seven different alanine mutants of TPX2 in parallel, which
were then used for afﬁnity determination by a direct binding assay
using Bio-Layer Interferometry (BLI) and by the FA competition assay.
RAD-TPX2 mutants, puriﬁed by IMAC chromatography and
buffer exchanged into the assay buffer, were used in direct binding
tests using BLI (Fig. 5a–c; Figs. S10a and S11). Since the His-tagged
RAD-TPX2 was used for immobilization on the BLI surface, in this
assay, the His6-tagged Aurora AD274N construct was replaced by the
untagged wild-type Aurora A kinase domain construct (Aurora
AWT, Fig. 5a).
These BLI experiments were able to determine afﬁnities of all the
TPX2 mutants (Fig. 5b; Table II). Mutations of Y8 and Y10 to ala-
nines had the most negative impact on the interaction, but removal
of any of these interacting side chains resulted in at least 20-fold
reduction in the afﬁnity between TPX2 and Aurora A, demonstrat-
ing their critical roles in this complex.
To conﬁrm the results of the BLI analyses, we used a competition
FA assay to determine afﬁnities for each of the seven alanine
mutants of the RAD-TPX2 in solution and compare these with the
values obtained with the wild-type RAD-TPX2 (Fig. 5d–f).
In order to perform competition binding experiments, we
assessed the afﬁnity of the Alexa Fluor 488-labeled TPX2 peptide
for wild-type Aurora A kinase domain. FA measurements were per-
formed by titrating increasing concentrations of the kinase into con-
stant concentration of labeled TPX2 peptide (10 nM). This yielded a
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Kd of 2.1 nM (Fig. 5d), in good agreement with previously reported
data (Anderson et al., 2007). This was conﬁrmed by ITC (Fig. S12)
and clearly shows that the afﬁnity of the TPX2 to Aurora A is
altered by the D274N mutation. D274 is part of the so-called DFG
motif in Aurora A and coordinates the Mg2+ ion in the ATP binding
site. It is likely that abolishment of Mg2+ binding has an allosteric
effect on TPX2 binding site, resulting in the signiﬁcant difference we
have observed in the binding afﬁnities. In the BLI experiments
Aurora A has a ~20 fold weaker afﬁnity to RAD-TPX2 compared
to the values determined in the FA assay using ﬂuorescently labeled
linear TPX2 peptide, suggesting that the BLI sensor surface may
have a negative effect on this interaction.
In the FA competition assay, the labeled wild-type TPX2 peptide
was competed by increasing concentrations of each of the eight
mutant RAD-TPX2 proteins. These experiments revealed that TPX2
mutants Y8A and Y10A, along with D11A, had the lowest afﬁnities
for the Aurora AWT kinase domain (Fig. 5e; Table II). Mutation of
these conserved tyrosines to alanines decreased the afﬁnity of TPX2
by a factor >300 (Table II). This was consistent with the results
obtained in the BLI experiments and was in line with the observa-
tions by Eyers and Maller that the hydrophobic residues Y8 and
Y10 were critical for activation of Aurora A kinase by TPX2 (Eyers
and Maller, 2004). Effects of the other mutated residues in TPX2
afﬁnity were in similarly good agreement with the BLI data.
Discussion
To extend the tool repertoire for the PPI studies, we have designed a
new peptide display system, termed ‘the RAD display’, which is
based on the RadA recombinase from P. furiosus. The thermal sta-
bility and design of the novel scaffold allows for high-level produc-
tion and rapid puriﬁcation of soluble display proteins in E. coli. The
RAD scaffold was demonstrated to be a well-expressed and well-
behaved protein that tolerates both short and long peptide insertions
as long as 45 amino acids in RAD-TPX2. Indeed, the TPX2 peptide
insertion is the longest reported one, along with the 42 residues dis-
played by the Afﬁmer scaffold (Hoffmann et al., 2010). We have
also been able to display a complete protein in this system, with sol-
uble expression and puriﬁcation of T4 lysozyme containing RAD
scaffold (data not shown). In this case, the thermal stability of the
whole construct was not retained, as would be expected whenever a
fully folded domain is inserted into the scaffold. We have also
expressed number of epitopes from structured part of TGF-β growth
factors successfully in this system, demonstrating the ability of the
RAD scaffold to facilitate soluble expression and stability of relatively
hydrophobic epitopes as well (Fig. S13). Using afﬁnity-tagged pro-
teins, parallel puriﬁcation can be easily achieved and also allows for
easy and rapid ‘semi-pure’ screening systems to be developed without
the need for multi-step protein puriﬁcation (Fig. 1, Fig. S10a).
As the displayed peptide is inserted in the middle of the scaffold
it is likely to be more protected from proteolysis when compared
with fusion of such peptide to either terminus of the protein, as a
ﬂexible ‘tail’. Further, stability of the scaffold will also be beneﬁcial
for long-term storage of the protein as well as for the development
of assays where the scaffold is likely to be exposed to harsh condi-
tions, such as regeneration of protein on an SPR sensor chip.
A unique cysteine in the scaffold allows for labeling in a controlled
and uniform manner using the well-established maleimide chemistry.
Labeling with biotin, either chemically through the cysteine or by
enzymatic modiﬁcation of the AviTag would allow interaction of the
scaffold with streptavidin, and the utilization of a wide variety of
technologies that take advantage of this high-afﬁnity interaction for
screening, binding, puriﬁcation and selection. Labeling with ﬂuores-
cent dyes will allow the protein to be used for various ﬂuorescence-
based binding assays, as demonstrated by our FA binding assays.
The scaffold allows presentation of the peptide in an oriented
fashion due to a spacer on the RAD display that separates the epi-
tope from the labeling or immobilization site in the N-terminus of
RAD display. We have shown through several complementary tech-
niques that epitopes in the RAD display scaffold interact with their
targets in a similar manner to isolated peptides. When analyzing the
relatively short CK2β peptide binding to CK2α kinase, the results
with the RAD display were more consistent across the different
experimental techniques, suggesting that for shorter epitopes immo-
bilization or derivatization of the peptide inﬂuences its properties
signiﬁcantly, resulting in less accurate measurements.
The LIC site in the various scaffold expression plasmids facili-
tates rapid generation of constructs using overlapping oligonucleo-
tides. As there appear to be few constraints with respect to the
inserted sequence, it is easy to construct libraries of epitopes, with
mutations in speciﬁc positions of the target sequence. Such libraries
(or panels) of variant epitopes could be used for the development of
higher afﬁnity binding variants of the original sequence or to probe
the speciﬁcity of residues in particular positions of the epitope, simi-
lar to what we have by alanine scanning of TPX2 epitope.
In conclusion, the RAD display serves as a ﬂexible and robust
platform for the selection or characterization of peptides in a variety
of applications ranging from basic research tool to drug discovery.
We envisage that RAD display could be useful in expression of bind-
ing epitopes in mammalian cells as well, for functional analysis of
loop epitopes, by providing a stable platform to ensure otherwise
completely unstructured peptides are not immediately destroyed.
The scaffold could be tagged with localization signals to direct it to
a desired subcellular location like the nucleus. Given that the RAD
scaffold tolerates a wide range of inserts, it could also be used as a
platform to display epitope libraries varying different length and
composition for the identiﬁcation of novel binders or for the deter-
mination of afﬁnity determinants in a high-throughput fashion.
Materials and methods
Construction of RAD display vectors
All oligonucleotide sequences are listed in Table S2. Point mutation
K144A in the active site mutation of the P. furiosus RadA (PfRadA,
Table II. Afﬁnities of TPX2 mutants towards wild-type Aurora A
TPX2 mutation Assay
FA BLI
KD (μM) KD (μM)
WT 0.002 0.046
Y8A >3.2 2.8
Y10A >3.2 11.0
D11A >3.2 1.1
F16A 0.3 0.82
F19A 1.77 0.87
W34A 1.17 0.84
F35A 1.11 1.1
Dissociation constants (KD) for different RAD-TPX2(7–43) mutants, determined
by using FA competition assay and by measuring direct binding with BLI.
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Uniprot: O74036) ATPase domain was created using overlapping
PCR with primer pairs RAD-K144A-F and RAD-K144A-R and sub-
cloned into pBAT4 expresson plasmid using the NcoI and XhoI sites
to create PfRadA K144A. Residues 108–350 of this construct were
ampliﬁed by PCR from pBAT-PfRadA3 K144A plasmid in two stages
to introduce the LIC site in the place of the L2 loop using primers
pRAD and pRAD-LIC2, and HAT2 and pRAD-LIC1 primers. For
constructs containing a free cysteine for labeling, pRAD1 primer was
replaced with primer pcRAD1. Ampliﬁed fragments were digested
with NcoI and XhoI and ligated into similarly digested pBAT4 or
pHAT vectors for untagged and His-tagged versions, respectively.
All constructs were conﬁrmed correct by sequencing. Vector
maps with sequences of the cloning site for display peptides are
shown in the Supplementary Material.
Cloning of RAD display constructs for TPX2 and CK2β
peptides
Peptide sequences to be displayed on the RAD scaffold were reverse
translated and codon optimized for E. coli expression. Redundancy in
the codons was utilized to maximize the speciﬁcity and stability of
dsDNA assembly from contiguous, overlapping, complementary syn-
thetic oligonucleotides and 5′ and 3′ ssDNA overhangs complementary
to the LIC-ready vector were added to the oligonucleotides constituting
the 5′ and 3′ ends of the insertion coding sequence (Table S2). The LIC
pRAD-TPX2 expression plasmid was digested with NcoI and NotI and
ligated into the pHAT plasmid digested with the same enzymes to pro-
duce a His6-tagged construct of RAD-TPX2. The resulting plasmid was
used as a template for PCR using primer pair pRAD-TPX2-F, pRAD-
TPX2-R or phRAD-TPX2-F and pRAD-TPX2-R. Alanine mutant var-
iants of this construct were then produced by site directed mutagenesis
using the pRAD-TPX2/(X#A) series of primers. PCR products were
digested with BspHI and XhoI for ligation with pHAT4-haXrn6
digested with NcoI and XhoI. Alanine mutant variants of this construct
were then produced by site directed mutagenesis using the pRAD-
TPX2/(X#A) series of primers. TPX2 mutants for alanine scanning
were inserted into RAD scaffold with His6-Avi-His6-tag to facilitate
stable immobilization with anti-penta-His sensors for BLI.
Expression of RAD display proteins
RAD display scaffolds with or without target peptide sequences
were expressed in BL21(DE3) cells containing pUBS520 plasmid
(Brinkmann et al., 1989) in 2xYT media supplemented with 100 μg/
ml ampicillin and 25 μg/ml kanamycin. Cultures were grown at
37°C to OD600 of 0.8 and induced with 0.4mM IPTG. Protein was
expressed for 3 h at 37°C and cells were harvested by centrifugation
at 4000×g for 10 min at 4°C. Cell pellets were stored at −80°C.
Puriﬁcation of untagged RAD display proteins
Frozen cell pellets were thawed, resuspended in 5ml/g of cells in
50mM Hepes pH 7.4, 150mM NaCl and lysed by three passages
through an Emulsiﬂex C5 homogenizer. Lysates were heated for 10
min at 65°C before centrifugation at 30 000×g at 4°C for 30min to
pellet precipitated E. coli proteins. The supernatant was dialyzed
against 10mM MES pH 6, 0.5mM EDTA, puriﬁed by cation
exchange chromatography over a 5-ml HiTrap SP column (GE
Healthcare) and eluted in a gradient from 0 to 1M NaCl in elution
buffer (10mM MES pH 6, 0.5mM EDTA). Peak fractions were
pooled, concentrated and further puriﬁed by SEC over Superdex 75
16/60 HiLoad (GE Healthcare) column equilibrated with size
exclusion buffer 10mM MES pH 6, 0.5 mM EDTA, 200mM NaCl,
1 mM DTT. Peak fractions were pooled, concentrated to 5–7mg/ml,
ﬂash frozen in liquid nitrogen and stored at −80°C.
Expression and puriﬁcation of His-tagged RAD display
proteins
Frozen cell pellets were resuspended in 5ml/g of cells in water and
lysed by three passages through an Emulsiﬂex C5 homogenizer.
Lysates were heated for 10 min at 65°C before centrifugation at
30 000×g at 4°C for 30 min to pellet precipitated E. coli proteins.
The supernatant was adjusted to 50mM Tris pH 8, 500mM NaCl,
1mM DTT, 40mM imidazole, applied on 0.5ml Ni Sepharose beads
(GE Healthcare), washed with 30ml 50mM Tris pH 8, 500mM NaCl,
1mM DTT, 40mM imidazole and eluted in 5ml buffer containing
50mM Tris pH 8, 500mMNaCl, 1mM DTT, 600mM imidazole.
For BLI experiments and competition FA assays eluted His-tagged
proteins were buffer exchanged into the BLI buffer and stored at 4°C.
For other binding assays proteins were further puriﬁed by SEC over
HiLoad Superdex 75 16/60 column (GE Healthcare) equilibrated
with size exclusion buffer 10mM MES pH 6, 0.5mM EDTA,
200mM NaCl, 1mM DTT. Peak fractions were concentrated to
5–7mg/ml, ﬂash frozen in liquid nitrogen and stored at −80°C.
Expression and puriﬁcation of CK2α kinase
Human CK2α kinase (residues 2-329) was expressed in BL21(DE3)
cells containing pUBS520 plasmid in 2xYT media supplemented with
100 μg/ml ampicillin and 25 μg/ml kanamycin. About 4 l of cell culture
were grown at 37°C until an OD600 of 0.6 when the temperature was
lowered to 25°C for 1 h before induction with 0.4 mM IPTG. Protein
was expressed for 18 h overnight at 25°C and the cells were harvested
by centrifugation at 4000×g for 10 min at 4°C. Cell pellets were
stored at −80°C until required when they were resuspended in 5ml/g
of cells in 100mMMES pH 6, 0.5mM EDTA and lysed by three pas-
sages through an Emulsiﬂex C5 homogenizer. Lysate was cleared by
centrifugation at 40 000×g at 4°C for 30 min. Clariﬁed lysate was
puriﬁed over a 5ml HiTrap SP column (GE Healthcare) and eluted by
a gradient to from 0 to 1M NaCl in 100mM MES pH 6, 0.5mM
EDTA over 30 column volumes. To stabilize the protein, NaCl was
added to 1M to the pooled elution peak fractions, which were conse-
quently dialyzed overnight against 100mM MES pH 6, 0.5M NaCl,
0.5mM EDTA. Protein was further puriﬁed by SEC over a Superdex
75 16/60HiLoad column (GE Healthcare) equilibrated with 20mM
Tris-HCl pH 8, 500mM NaCl, 2mM DTT. CK2α kinase required a
buffer containing at least 500mM NaCl to remain soluble. Puriﬁed
CK2α had a strong absorption peak at 260 nM even after the size
exclusion step, which we attributed to the possible contamination by
nucleotides bound to the active site. The peak disappeared though
after prolonged protein dialysis in the size exclusion buffer overnight
at 4°C. Peak fractions were pooled, concentrated to 10mg/ml and
ﬂash frozen in liquid nitrogen for storage at −80°C.
Expression and puriﬁcation of Aurora A
Kinase dead human Aurora AD274N mutant (residues 122-403)
was cloned into pHAT5 vector in frame with a C-terminal 6xHis-
tag. Protein was expressed in BL21(DE3) cells containing pUBS550
plasmid cultured in 2xYT media supplemented with 100 μg/ml
ampicillin and 25 μg/ml kanamycin. About 4 l of cell culture were
grown at 37°C until an OD600 of 0.6 when the temperature was
lowered to 25°C for 1 h before induction with 0.4mM IPTG.
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Protein was expressed for 18 h overnight and the cells were har-
vested by centrifugation. Cell pellets were stored at −80°C until
required when they were resuspended in 5ml/g of cells in 50mM
Tris-HCl 8, 0.5M NaCl, 20mM imidazole and lysed by 3 passages
through an Emulsiﬂex C5 homogenizer. Lysate was cleared by cen-
trifugation at 30 000×g at 4°C for 30 min, applied on a 5ml
HisTrap HP column (GE Healthcare). Protein was eluted over 30
column volumes in a 40–600mM imidazole gradient in 50mM
Tris-HCl pH 8, 0.5M NaCl. DTT was added to 5mM to the
pooled peak fractions that were further puriﬁed by SEC over a
HiLoad Superdex 75 column 16/60 (GE Healthcare) equilibrated
with 20mM Tris-HCl pH 8, 500mM NaCl, 2mM DTT. Peak frac-
tions were pooled, concentrated to 7mg/ml and aliquoted before
ﬂash freezing in liquid nitrogen for storage at −80°C. We observed
heavy protein precipitation even in a buffer containing 500mM
NaCl and therefore kept the protein concentration at 7mg/ml or
less. Untagged wild-type Aurora A expression and puriﬁcation has
been described previously (Janecek et al., 2016).
Production of TPX2 peptide
Recombinant peptide was produced using a method described else-
where (Kuliopulos and Walsh, 1994). DNA encoding for residues
7–43 of human TPX2 (LSYSYDAPSD FINFSSLDDE GDTQNIDSWF
EEKANLENLK GGGCQM) was cloned into pET31b expression vec-
tor (Novagen) and expressed in BL21(DE3) cells. 2 l of cell culture
were grown in 2xYT media supplemented with 100 μg/ml ampicillin
and 25 μg/l kanamycin at 37°C. Protein expression was induced
at OD600 of 0.6 with 0.4mM IPTG. Protein was expressed for 4 h at
37°C and the cells were harvested by centrifugation at 4000×g for
10 min at 4°C. Cell pellet was resuspended in water, lysed by
three passages through an Emulsiﬂex C5 homogenizer and centrifuged
at 30 000×g, 4°C for 30 min. Obtained inclusion bodies pellet con-
taining fusion protein was dissolved in 20 mM Tris-HCl pH 8,
500mM NaCl, 5mM imidazole, 6M guanidinium-HCl. Insoluble
protein was removed by centrifugation 12 000 x g, 10 min at 4°C and
supernatant was loaded onto 15ml Ni-NTA beads (Qiagen). The col-
umn was washed with 150ml of the loading buffer, and the protein
was eluted with 20mM Tris-HCl pH 8, 500mM NaCl, 300 mM
imidazole, 8M urea. The eluted protein was dialyzed overnight against
10 l water at 4°C and pelleted by centrifugation at 2000×g, 10min,
4°C. 2 g of the pellet was solubilized in 60ml of 80% formic acid, 2 g
of CNBr was added and stirred for 20 h. The reaction mixture was
evaporated to dryness, the protein was resuspended in 20ml of 5%
acetonitrile, 0.1% TFA and stirred for 1 h at room temperature. The
suspension was centrifuged at 12 000×g for 10min at 4°C and puri-
ﬁed by reverse-phase HPLC on a 4.6 × 250mm Vydac 5 μm 300Å
C18 reversed-phase column (HiChrom Ltd, UK) using 5–90% aceto-
nitrile gradient. Fractions containing peptide were pooled and dried
using centrifugal vacuum evaporator at room temperature followed by
re-suspension in 10mM HEPES pH 7.4, 100mM NaCl.
Labeling with Alexa Fluor 488
TPX2 peptide, TPX2 and CK2β display proteins containing free N-
terminal cysteines were labeled with Alexa Fluor 488 (ThermoFisher
Scietiﬁc). About 100 μg peptide or protein in 500 μl sodium phos-
phate pH 6.75, 150mM NaCl were labeled using 30-fold excess of
the maleimide dye. The reactions was allowed to proceed for 1 h at
room temperature and the Alexa Fluor 488-maleimide was removed
by dialysis using 3-kDa molecular weight cut-off membrane against
10mM Tris pH 8, 250mM NaCl buffer. Protein and peptide
samples were dialyzed for 3 h at room temperature and further puri-
ﬁed by SEC using Superdex 75 GL 10/300 or Superdex peptide 10/
300 GL column (GE Healthcare). Labeled peptides and proteins
were concentrated to 100 μM, ﬂash frozen in liquid nitrogen and
stored at −80°C. The concentration of labeled peptide or proteins
and degree of labeling was determined by measuring the absorbance
at 280 and 495 nm.
Sedimentation velocity analytical ultracentrifugation
Protein samples were prepared for SV AUC experiments by buffer
exchanging of concentrated protein stocks into 20mM HEPES pH
7.5, 500mM NaCl. CK2α kinase and RAD-CK2β display were
loaded in cell assemblies at 6 and 14.3 μM concentration, respect-
ively, and the complex was formed by mixing 5 μM of each of the
two proteins together. Aurora AD274N and RAD-TPX2 were loaded
in cell assemblies at 10 and 25 μM concentration, respectively, and
the complex formed by mixing the two proteins at 10 μM each.
SV AUC experiments with absorbance detection were performed
in an Optima XL-1 analytical centrifuge at 50 000 rpm at 20°C after
60 min equilibration step. A total of 100 scans were acquired at 280 nm.
Data were analyzed using the SEDFIT software (Brown and Schuck,
2008) and the continuous size-distribution option. Buffer density and
viscosity at 20°C were calculated using SEDNTERP.
Analytical SEC
Puriﬁed protein samples, either as individual proteins or equimolar mix-
tures, were separated by analytical SEC over an Superdex 75 5/150 size
exclusion column (GE Healthcare) equilibrated with 20mM HEPES
pH 7.5, 500mM NaCl. Fractions from the peaks from each run were
analyzed by SDS-PAGE with puriﬁed proteins as standards. The column
was calibrated using molecular weight standards (blue dextran, bovine
serum albumin, carbonic anhydrase, cytochrome C and aprotonin,
Sigma-Aldrich cat. MWGF70) and the calibration curve used to esti-
mate the molecular weights of the three samples (Fig. S5).
Isothermal titration calorimetry
All ITC experiments were performed on itc200 instrument (GE
Healthcare). Prior to ITC titration, proteins and peptides were buffer
exchanged into 10 mM HEPES pH 7.4, 500mM NaCl, 0.05% P20
surfactant. ITC experiments with Aurora Awt kinase were performed
in buffer containing 50mM HEPES pH 7.4, 100mM Mg
(CH3COO)2, 100mM NaCl, 1mM ATP, 1mM DTT, 0.01% v/v
P20. Titrations experiments were conducted at 25°C with an initial
0.4 μl injection at a duration of 0.8 s, followed by 19 or 29 injections
of 2 μl at a duration of 4 s with 120, 180 or 200 s spacing for Aurora
AD274N, Aurora AWT and CK2α kinase binding assays, respectively.
In the Aurora AD274N and Aurora AWT binding assays, 50 μM solu-
tion of the titrant was injected into 5 μM kinase solution in the cell.
For the determination of binding afﬁnity between CK2α and its inter-
acting partners, 100 μM of CK2β peptide or RAD-CK2β display were
titrated into 10 μM CK2α kinase solution. Binding isotherms were ﬁt
by non-linear regression using the single-site model provided by
ORIGIN software (Origin Lab). The stoichiometry of the interaction
(N), equilibrium association constant (KA) and change of enthalpy
(ΔH) were ﬂoated during the ﬁtting.
Surface plasmon resonance
SPR analyses were conducted using a Biacore T100 instrument (GE
Healthcare) using CM5 sensor chips to which cRAD display
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proteins were immobilized through their unique cysteine residues.
All coupling reagents were purchased from GE Healthcare: N-ethyl-
N′-dimethylaminopropylcarbodiimide (EDC), 2-(2-pyridinyldithio)
ethaneamine hydrochloride (PDEA), N-hydroxysuccinimide (NHS).
All immobilizations were conducted at 25°C in running buffer
10mM HEPES pH 7.4, 500mM sodium chloride, 0.05% P20. Two
CM5 sensor chips were used for the experiments. Peptides and RAD
scaffold displaying the peptides were covalently immobilized via free
cysteine on the sensor surface in cells 2 and 4, respectively. Cells 1
and 3 were derivatized with cysteine only and served as reference
surfaces. Active and reference cells were created automatically using
the immobilization surface preparation Wizard software.
Immobilization levels for cells 2 and 4 ranged from 240 to 400 RU.
For binding studies, 2.5 μM protein stocks of CK2α and Aurora
AD274N were prepared in running buffer from which twofold serial
dilutions were made spanning concentrations from 2.5 nM to
2.5 μM. Each concentration was injected at 10 μl/min for 1400 s
(CK2α) and 1500 s (Aurora AD274N) across all four cells. The dis-
sociation step was 180 s after which sensor surfaces were regener-
ated by injecting 3M MgCl2 solution 3 times for 30 sat 60 μl/min.
All sensograms were processed using double-referencing method fol-
lowed by dissociation constant determination using 1:1 steady-state
afﬁnity model implemented into the BIAevaluation 3.0 software. To
minimize the effect of unspeciﬁc binding, the CK2α data was ana-
lyzed at 200 s post-injection. Aurora A binding to TPX-2 peptide
and RAD-TPX-2 were analyzed also using kinetic data with heter-
ogenous ligand model, with data presented in the Supplementary
Material.
Fluorescence anisotropy
A stock solution of Alexa Fluor 488-labeled peptide or display pro-
teins was diluted in assay buffer to concentration of 20 nM. For
both studies, 10mM HEPES pH 7.4, 500mM NaCl, 1mM DTT,
0.05% P20 buffer from was used. Protein concentrations ranged
from 2 nM to 2 μM for CK2α and 2 nM to 1.5 μM for Aurora
AD274N. Samples were prepared in a black polysterene, ﬂat-
bottomed, 96-well half-area plate (Corning Inc.) and incubated for
15min at room temperature prior measurements. FA was measured
using PheraStar spectroﬂuorimeter plate reader (BMG Laboratories,
Durham, NC) equipped with polarization ﬁlters (excitation 485 nm,
emission 520 nm). Dissociation constants were calculated in pro Fit
(Quantum Soft) by ﬁtting experimental data to 1:1 binding model
equation.
FA competition assay
FA binding and competition experiments were performed at 25°C as
described above in 50M HEPES pH 7.4, 0.1M Mg(CH3COO)2,
100 mM NaCl, 1 mM ATP, 1 mM DTT, 0.01% v/v P20.
In order to perform competition experiments, the afﬁnity of the
Alexa Fluor 488-labeled TPX-2 peptide for the kinase domain of
Aurora AWT was determined by titrating increasing concentration of
the kinase into constant 10 nM concentration of labeled TPX2 pep-
tide. Direct binding measurements were performed using a constant
peptide concentration. The concentration of protein titrant was
adjusted based on the dissociation constant observed in trial experi-
ments. Binding isotherms were ﬁtted to a standard quadratic
equation for a single-site.
Competitive binding experiments were performed using 10 nM
Alexa Fluor 488-labeled TPX2 peptide and 50 nM Aurora AWT,
determined to give ~90% saturation of binding in the absence of a
competitor. The interaction between the protein and the TPX2 pep-
tide was then challenged using eight different variants of the RAD-
TPX2 protein as competitors. Serial dilutions of each competitor
were mixed with Aurora A and labeled TPX-2 peptide with the ﬁnal
concentrations of the competitor ranging from 195 nM to 25 μM. Ki
for individual mutants was obtained from ﬁtting of experimental
competitive binding isotherms into the equation derived by Wang
(1995).
Bio-Layer Interferometry
Octet RED96 (ForteBio) instrument was used for BLI analysis for
double His-tagged RAD-TPX2/Aurora AWT interactions.
Experiments were performed using Anti-Penta-HIS biosensors
(ForteBio), which were regenerated with 10mM glycine, pH 1.7.
IMAC puriﬁed RAD proteins displaying wild-type sequence or ala-
nine mutants of the TPX2 were buffer exchanged into 50mM
HEPES pH 7.4, 500mM NaCl, 100 mM Mg(CH3COO)2, 0.5 mM
ATP, 0.5mM TCEP, 0.05% P20 (assay buffer). For binding assays
pre-wet sensors were loaded with double His-tag labeled proteins at
1 μM in assay buffer. Dilution series (from 0 to 500 or 5000 nM) of
Aurora AWT kinase construct without His-tag was prepared in the
assay buffer and following experimental setup was used for each
measurement cycle: regeneration 3 × 5 s, baseline monitoring 120 s,
sample loading 200 s, baseline monitoring 150 s, ligand binding
(association) 400 s and ligand dissociation 600 s, followed by regen-
eration and the next cycle. Regenerated Anti-Penta-HIS biosensors
were used to perform double referencing. Data was processed using
ForteBio Analysis 7.1 software and dissociation constants were cal-
culated in pro Fit (Quantum Soft) by ﬁtting experimental data to 1:1
binding model equation.
Supplementary data
Supplementary data are available at Protein Engineering, Design and
Selection online.
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